Back

Pluripotent Stem Cell-Derived Cardiovascular Progenitors Diffferentiated On Laminin 221 Regenerate And Improve Function Of Infarcted Swine Hearts

Yap, L.; Chong, L. Y.; Tan, C.; Adusumalli, S.; Seow, M.; Guo, J.; Cai, Z.; Loo, S. J.; Lim, E.; Lath, N.; Ye, L.; Petretto, E. G.; Tryggvason, K.

2021-04-29 cell biology
10.1101/2021.04.29.441908 bioRxiv
Show abstract

BackgroundIschemic heart disease is a huge global burden where patients often have irreversibly damaged heart muscle. State-of-the-art technology using stem cell-derived products for cellular therapy could potentially replace damaged heart muscle for regenerative cardiology. Methods and ResultsPluripotent human embryonic stem cells (hESCs) were differentiated on a laminin LN521+221 matrix to cardiovascular progenitors (CVPs). Global transcriptome analyses at multiple time points by single-cell RNA-sequencing demonstrated high reproducibility (R2 > 0.95) between two hESCs lines. We identified several CVP signature genes as quality batch control parameters which are highly specific to our CVPs as compared to canonical cardiac progenitor genes. A total of 200 million CVPs were injected into the infarcted region caused by permanent ligation of the coronary arteries of 10 immunosuppressed pigs and maintained for 4- and 12-weeks post transplantation. The transplanted cells engrafted and proliferated in the infarcted area as indicated by IVIS imaging, histology staining and spatial transcriptomic analysis. Spatial transcriptomic analysis at 1 week following transplantation showed that the infarcted region expressed human genes in the same area as immunohistology sections. Heart function was analyzed by magnetic resonance imaging (MRI) and computerized tomography (CT). Functional studies revealed overall improvement in left ventricular ejection fraction by 21.35 {+/-} 3.3 %, which was accompanied by significant improvements in ventricular wall thickness and wall motion, as well as a reduction in infarction size after CVP transplantation as compared to medium control pigs (P < 0.05). Immunohistology analysis revealed maturation of the CVPs to cardiomyocytes (CMs) where the human grafts aligned with host tissue forming end-to-end connections typical for heart muscle. Electrophysiology analyses revealed electric continuity between injected and host tissue CMs. Episodes of ventricular tachyarrhythmia (VT) over a period of 25 days developed in four pigs, one pig had persistent VT, while the rest remained in normal sinus rhythm. All ten pigs survived the experiment without any VT-related death. ConclusionsWe report a highly reproducible, chemically defined and fully humanized differentiation method of hESCs for the generation of potent CVPs. This method may pave the way for lasting stem cell therapy of myocardial infarction (MI) in humans. Clinical PerspectiveO_ST_ABSWhat is New?C_ST_ABSO_LIWe present a highly reproducible, chemically defined and fully humanized laminin-based differentiation method for generation of large amounts of cardiovascular progenitors (CVP); 20 million cells in a 10 cm2 culture dish which were used for a preclinical study in pigs. C_LIO_LITransplantation of the CVPs into the myocardial infarcted pig hearts yields maturation of the progenitor cells to cardiomyocytes (CMs) and improved cardiac function (21.35 {+/-} 3.3 % LVEF improvement) using only 200 million CVPs. C_LIO_LITemporary episodes of ventricular arrhythmia (50%) were observed after CVP transplantation. No fatal ventricular arrhythmia occurred. C_LI What are the clinical implications?O_LIOur laminin-based approach generated potent CVPs in vivo and largely restored function of the damaged heart. C_LIO_LICardiovascular progenitors may provide a new and safe therapeutic strategy for myocardial infarction. C_LIO_LIThe results may have a significant impact on regenerative cardiology. C_LI

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Journal of Molecular and Cellular Cardiology
39 papers in training set
Top 0.1%
14.6%
2
Frontiers in Cardiovascular Medicine
49 papers in training set
Top 0.2%
14.2%
3
Circulation
66 papers in training set
Top 0.4%
10.0%
4
Journal of the American Heart Association
119 papers in training set
Top 0.9%
8.1%
5
Stem Cells Translational Medicine
11 papers in training set
Top 0.1%
4.8%
50% of probability mass above
6
Stem Cell Reports
118 papers in training set
Top 0.2%
4.3%
7
Stem Cell Research & Therapy
30 papers in training set
Top 0.1%
3.9%
8
Stem Cell Research
16 papers in training set
Top 0.1%
3.6%
9
PLOS ONE
4510 papers in training set
Top 43%
2.9%
10
Scientific Reports
3102 papers in training set
Top 51%
2.1%
11
Stem Cells
28 papers in training set
Top 0.2%
1.7%
12
Cell Proliferation
12 papers in training set
Top 0.1%
1.7%
13
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.3%
1.6%
14
Cardiovascular Research
33 papers in training set
Top 0.6%
1.5%
15
Arteriosclerosis, Thrombosis, and Vascular Biology
65 papers in training set
Top 1%
1.3%
16
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 5%
1.3%
17
Journal of Visualized Experiments
30 papers in training set
Top 0.4%
1.2%
18
Cytotherapy
14 papers in training set
Top 0.2%
1.2%
19
Nature Communications
4913 papers in training set
Top 60%
0.9%
20
Cells
232 papers in training set
Top 6%
0.8%
21
Cell Reports Medicine
140 papers in training set
Top 9%
0.7%
22
Biochemical and Biophysical Research Communications
78 papers in training set
Top 2%
0.7%
23
Toxicology and Applied Pharmacology
13 papers in training set
Top 0.3%
0.6%
24
Tissue Engineering Part A
15 papers in training set
Top 0.2%
0.6%
25
Toxicological Sciences
38 papers in training set
Top 0.7%
0.6%
26
Advanced Healthcare Materials
71 papers in training set
Top 2%
0.6%
27
Journal of Personalized Medicine
28 papers in training set
Top 2%
0.6%
28
Biomedicines
66 papers in training set
Top 4%
0.6%